Clinical trials: Pregnancy, High-risk
Polycystic Kidney, Autosomal Dominant
The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease
The aim of the study is to test the following hypotheses: 1. that the function and/or regulation of AQP2 and /or ENaC in the principal cells is abnormal in autosomal dominant polycystic kidney disease. 2.
- Trial name
- NCT00410007
- Testing
- High Sodium Diet, Low Sodium Diet, Hypertonic saline infusion
- Where
- Denmark
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Carolina Cannillo
Apnea of Prematurity
Apnea of Prematurity Results in Respiratory Distress and Cyanosis. Caffeine Citrate Can Treat It.
High-dose caffeine citrate is more effective than low-dose caffeine citrate in the treatment of apnea of prematurity (AOP). The high-dose group showed fewer apnea episodes, higher extubation success rate, lower extubation failure…
- Trial name
- AOP (NCT06905496)
- Testing
- High-Dose, Low Dose
- Where
- Pakistan
- Volunteers
- 114 people
- Sponsor
- Nishtar Medical University
Epithelial Ovarian Cancer, Peritoneal Cancer
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine (MIRV) vs. IC chemotherapy in participants with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or…
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- MIRASOL (NCT04209855)
- Testing
- Mirvetuximab Soravtansine, Paclitaxel, Topotecan
- Where
- 214 sites in United States, Australia and 19 more
- Volunteers
- 453 people
- Sponsor
- AbbVie
Invasive Bladder Cancer, Bladder Cancer
Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin
The standard treatment of muscle invasive bladder cancer is to administer chemotherapy for approximately 3 months then to have surgery to remove the bladder.
- Trial name
- NCT02030574
- Testing
- Gemcitabine and fractionated cisplatin (combination treatment)
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Brown University
Preterm Birth
Oxygen Assist Module in Preterm Infants on High Flow Nasal Cannula Support.
Oxygen treatment is common in babies born early (preterm) and requiring intensive care. Having too much or too little oxygen can increase the risk of damage to the eyes and lungs, and contribute to death or disability.
- Trial name
- ROAM (NCT04687618)
- Testing
- High Flow Nasal Cannula withAutomatic control of FiO2 using OAM, High Flow Nasal Cannula with manual control of FiO2
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- South Tees Hospitals NHS Foundation Trust
Ovarian Cancer, Peritoneal Cavity Cancer
Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer
RATIONALE: Giving colony-stimulating factors, such as G-CSF help stem cells move from the patient's bone marrow to the blood so they can be collected and stored.
- Trial name
- NCT00652691
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Volunteers
- 48 people
- Sponsor
- Mayo Clinic
Chronic Kidney Disease, Diabetic Nephropathy
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study. The objective of the study is to evaluate the efficacy and safety of once daily administration of atrasentan tablets (low dose and high dose) compared…
- Trial name
- RADAR (NCT01356849)
- Testing
- Atrasentan
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 149 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Endometrial Cancer, Serous Adenocarcinoma
Niraparib in High-grade Endometrial Cancer Trial
The study will investigate the effect of niraparib on tumor tissue in chemotherapy naïve, newly diagnosed, high-grade endometrial cancer patients.
- Conditions
- Endometrial Cancer, Serous Adenocarcinoma, Uterine Neoplasm
- Trial name
- NIREC (NCT05289648)
- Testing
- Niraparib oral capsule
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
End-stage Kidney Disease, CD4 T Cells
Effects of High Cut-off (HCO) Hemodialysis on Central Memory CD4+ T and Treg Cells in Patients With End-stage Kidney Disease
In this study, the investigators will evaluate whether CD4+ TCM producing effector cytokines can be distinguished on the basis of their expression of the IL-7 receptor alpha-chain (CD127).
- Conditions
- End-stage Kidney Disease, CD4 T Cells, Central Memory T Cells, Regulatory T Cells
- Trial name
- NCT01103076
- Testing
- Polyamide HD membrane
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier du Centre du Valais
Subarachnoid Hemorrhage, Acute Kidney Injury
A Low ChloridE hyperTonic Solution for Brain Edema
This pilot study will compare the two hypertonic solutions currently used for subarachnoid hemorrhage (SAH) - related complications and to determine if the reduction of chloride load is safer, and as efficacious as the classic…
- Trial name
- ACETATE (NCT03204955)
- Testing
- Sodium chloride /sodium acetate (16.4%), Sodium chloride (23.4%), PlasmaLyte
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Emory University
COVID-19
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
The purpose of this study is to learn about the side effects (safety) of the study medicine PF-07321332 (nirmatrelvir)/ritonavir for the treatment of mild to moderate COVID-19 infection in adults with severe renal impairment.
- Trial name
- NCT05487040
- Testing
- PF-07321332 (nirmatrelvir)/ritonavir
- Where
- 52 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
Opioid-use Disorder, Neonatal Abstinence Syndrome
MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study
This is a multi-center prospective comparative cohort study examining the safety, efficacy, pharmacokinetics, and pharmacogenomics of naltrexone for pregnant women with opioid use disorder.
- Conditions
- Opioid-use Disorder, Neonatal Abstinence Syndrome, Pregnancy, High Risk, Alcohol Use Disorder
- Trial name
- NCT03718104
- Testing
- Pharmacokinetic analysis, Safety and Efficacy, Genetic and epigenetic analysis
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Boston Medical Center
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
SL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum…
- Conditions
- Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer
- Trial name
- NCT05483933
- Testing
- Pegylated Liposomal Doxorubicin + SL-172154, Mirvetuximab + SL-172154
- Where
- 21 sites in United States, Canada and 2 more
- Volunteers
- 86 people
- Sponsor
- Shattuck Labs, Inc.
Type 2 Diabetes, Cardiovascular Complication
Effects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community
The Effects and Safety of Diabetic GUideline Algorithm Implementation in the Community (GUARD-Community) study is a 2-arm, cluster-randomized control trial to evaluate the effect and safety of guideline algorithm intervention…
- Conditions
- Type 2 Diabetes, Cardiovascular Complication, Diabetic Kidney Disease
- Trial name
- GUARD (NCT05349955)
- Testing
- Intensive guideline algorithm implementation, Conventional guideline algorithm implementation
- Where
- 13 sites in China
- Volunteers
- 5,600 people
- Sponsor
- Shanghai Zhongshan Hospital
Chronic Kidney Disease Stage 5, End Stage Renal Disease
CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients
The main purpose of this trial is to determine whether the addition of the VIEWER virtual care platform to usual care will lead to a reduction in composite emergency department (ED) visits and/or hospitalizations/or increase the…
- Trial name
- VIEWER (NCT05726526)
- Testing
- VIEWER virtual care platform
- Where
- 5 sites in Canada
- Volunteers
- 340 people
- Sponsor
- University of Manitoba
Ovarian Cancer, Fallopian Tube Cancer
Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients
This is a randomized Phase I/II study designed to assess the induction of an anti-tumor immune response; the effect of cyclophosphamide on the vaccine; and to assess safety in subjects with advanced ovarian cancer or primary…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- DC-Ova (NCT00478452)
- Testing
- DC-Ova, DC Ova with Cyclophosphamide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Pennsylvania
Placenta Accreta Spectrum
High vs. Low Segmental Hysterotomy: Impact on Uterine Wall Defects Post-Cesarean
The purpose of this clinical trial is to compare the incidence of defects in the uterine wall at the site of the scar (niche) and surgical complications when using high-segment versus low-segment hysterotomy, with both…
- Trial name
- HISEAL (NCT06620432)
- Testing
- Low segment hysterotomy, High segment hysterotomy, Crossed hysterorrhaphy
- Where
- Colombia
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Fundacion Clinica Valle del Lili
Postnatal Growth Restriction
Impact of Hindmilk on Weight Gain Among Moderate to Very Preterm Infants in Zambia
The primary hypothesis is that very preterm infants between 28 0/7 to 31 6/7 weeks with a birth weight from 1000-1999 grams allocated to the HV breastmilk group (200-240 mL/kg/day) until hospital discharge or 40 weeks'…
- Trial name
- NCT05403684
- Testing
- High-volume breastmilk
- Where
- Zambia
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Non-muscle Invasive Bladder Cancer, Urinary Biomarker
Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor
The study aims to evaluate the potential clinical impact of a highly sensitive urinary marker, the Xpert Bladder Cancer Monitor, regarding possible reduction in number of flexible cystoscopies in an outpatient setting without…
- Trial name
- SEALS Xpert (NCT04100733)
- Testing
- Xpert Bladder Cancer Monitor, Flexible cystoscopy (WL/NBI) and urinary cytology
- Where
- 3 sites in Denmark
- Volunteers
- 392 people
- Sponsor
- Jørgen Bjerggaard Jensen
Nephropathy
Interest of Remote Ischemic Preconditioning for Prevention of Contrast Medium-induced Nephropathy in High Risk Patients
Diagnostic imaging for vascular investigations and endovascular procedures frequently require the use of contrast medium. Besides contrast medium-induced hypersensitivity, an acute kidney injury can appear: the contrast-induced…
- Trial name
- IPC-Angio (NCT02470247)
- Testing
- Remote Ischemic Preconditioning (RIPC)
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Rennes University Hospital